Full-Time

ANZ Head of Planning

Posted on 12/13/2025

Thermo Fisher Scientific

Thermo Fisher Scientific

10,001+ employees

Supplies laboratory instruments, reagents, diagnostics

No salary listed

Melbourne VIC, Australia

In Person

Category
Operations & Logistics (1)
Requirements
  • Bachelor’s degree in supply chain management, Industrial Engineering, Science preferred
  • 10+ years of relevant professional experience leading Planning & SIOP, ideally including in a sales/distribution business model
  • Experience operating at a senior management level and being a member of a leadership group
  • Demonstrated track record in shifting business performance from a low to a high sustainable performance, in tough circumstances
  • Strong PPI, Lean and or Six Sigma working experience with demonstrated achievement of continuous improvement through utilization of Lean tools
  • Experience in leading teams of managers and individual contributors, with a track record of attracting and developing talent, developing bench strengths and leading a complex, diverse and dispersed workforce
  • Experience handling Third Party Suppliers and Global Manufacturing partners
  • Strong interpersonal and communication skills, with ability to influence optimally at all levels of the organization
  • Strong project management skills with the ability to develop strong support for change
  • Strong analytical, data management and organizational skills. Significant experience of value stream management, data collection and analysis in ERP systems
  • Demonstrate Thermo Fisher Scientific values - Integrity, Intensity, Innovation and Involvement. Demonstrates visible role model leadership characteristics
  • Experience of working in a global and matrix organization with a decentralized model
  • Experience in complex ERP Implementation and/or upgrades strongly preferred
  • Implement OHS policies and procedures and ensure a safe and healthy workplace environment
Responsibilities
  • Own the SIOP framework across all pillars – demand, supply, product, reconciliation, and business review
  • Align Long-Term Planning with business STRAP & AOP goals and operational capability
  • Lead short term (S&OE) and long-term planning (SIOP) across demand, supply, finance, integrated reconciliation and management reviews
  • Present planning scenarios and recommendations to executive team members to drive informed decisions
  • Champion continuous improvement and operational excellence in planning systems, processes, and culture
  • Act as a central liaison across Sales, Marketing, Finance, Operations, Procurement, and HR to ensure unified planning outcomes
  • Develop and implement comprehensive supply chain planning strategies
  • Lead inventory management to maintain optimal levels
  • Ensure alignment of supply chain plans with business objectives
  • Develop and analyse demand forecasts and adjust supply strategies accordingly
  • Supervise and report on supply chain critical metrics
  • Lead, mentor, and develop the supply chain planning team
  • Coordinate with suppliers for timely material delivery
  • Apply sophisticated planning software for production scheduling
  • Develop and implement contingency plans for supply chain disruptions
  • Conduct regular collaborator meetings on supply chain performance
  • Stay updated on industry trends and supply chain advancements
  • Evaluate and negotiate supplier and service provider contracts in collaboration with Procurement
  • Drive initiatives for continuous improvement in supply chain planning
  • Ensure compliance with supply chain regulations and standards
  • Strategic Planning: Develop and implement supply chain strategies that align with overall business objectives, focusing on demand forecasting, inventory optimization, and logistics management
  • SIOP Process Leading the implementation and maturity of the entire SIOP cycle, including pre-SIOP and monthly SIOP meetings
  • Demand Planning: Lead the demand planning process, applying forecasting techniques and collaborating with sales and marketing teams to ensure accurate demand projections
  • Inventory Management: Optimize inventory levels across the supply chain to minimize costs, reduce waste, and ensure product availability to meet customer demand
  • Supplier Relationship Management: Build and maintain strong relationships with suppliers and ensuring timely and reliable supply of materials
  • Performance Management: Develop and track key performance indicators (critical metrics) to monitor supply chain performance, identify areas for improvement, and drive continuous optimization
  • Team Leadership: Lead and mentor a team of supply chain professionals, fostering a collaborative and hard-working work environment
  • Cross-functional Collaboration: Collaborate with other departments, such as sales, marketing, and operations, to ensure alignment and flawless integration of supply chain activities
  • Cost Optimization: Find opportunities to decrease supply chain costs through process improvements, negotiating with suppliers, and optimizing inventory
  • Risk Management: Develop and implement risk mitigation strategies to address potential disruptions in the supply chain, such as natural disasters or supplier issues
  • Frequent Contacts: Internal ANZ Senior Leadership; Operations – Customer Care, Logistics, Master-data, QARA, Manufacturing, Procurement; Commercial - Product Managers, Product Specialists, Service Operations & Engineers; Finance, HR, IT; External Global and regional Manufacturing & Planning Leaders; Freight forwarders, Offshore BPO Planning team; Customers
  • Minimum Requirements/Qualifications: Bachelor’s degree in supply chain management, Industrial Engineering, Science preferred; 10+ years of relevant professional experience leading Planning & SIOP, ideally including in a sales/distribution business model; Experience operating at a senior management level and being a member of a leadership group; Demonstrated track record in shifting business performance from a low to a high sustainable performance, in tough circumstances; Strong PPI, Lean and or Six Sigma working experience with demonstrated achievement of continuous improvement through utilization of Lean tools; Experience in leading teams of managers and individual contributors, with a track record of attracting and developing talent, developing bench strengths and leading a complex, diverse and dispersed workforce; Experience handling Third Party Suppliers and Global Manufacturing partners; Strong interpersonal and communication skills, with ability to influence optimally at all levels of the organization; Strong project management skills with the ability to develop strong support for change; Strong analytical, data management and organizational skills. Significant experience of value stream management, data collection and analysis in ERP systems; Demonstrate Thermo Fisher Scientific values - Integrity, Intensity, Innovation and Involvement. Demonstrates visible role model leadership characteristics; Experience of working in a global and matrix organization with a decentralized model; Experience in complex ERP Implementation and/or upgrades strongly preferred; Qualifications & Experience; Implement OHS policies and procedures and ensure a safe and healthy workplace environment.
Desired Qualifications
  • Strong leadership skills to inspire and empower teams, provide clear direction, and deliver results
  • Critical thinking and ability to develop and implement long-term plans aligned with business strategy
  • Proficiency in operational excellence to implement & optimize S&OP process
  • Excellent communication and social skills to collaborate with cross-functional teams and external partners
  • Knowledge of supply chain management principles and practices, including procurement, logistics and customer service
  • Adaptability to thrive in a fast-paced environment, adopt new technologies, and navigate through challenges effectively
  • In-depth knowledge and experience in PPI methodologies such as Lean, Six Sigma, DMAIC, and Kaizen
  • Strong analytical and problem-solving skills, with the ability to apply PPI tools and methodologies to drive sustainable improvements
  • Excellent project management skills, including the ability to prioritize and lead multiple projects simultaneously
  • Strong leadership and communication skills, with the ability to influence and inspire teams to adopt PPI principles and motivate change
  • Ability to successfully collaborate and establish relationships at all levels of the organization
  • Continuous learning mentality, staying updated on leading PPI practices and industry trends
  • Strong data analysis and interpretation skills, with proficiency in using data management tools and ERP systems
  • Ability to work in a global and matrixed organization, navigating through decentralized structures
Thermo Fisher Scientific

Thermo Fisher Scientific

View

Thermo Fisher Scientific provides life sciences tools and services for research, healthcare, and industry. Its products include laboratory instruments, reagents, consumables, and software for activities like protein biology, PCR, sequencing, and bioprocessing. It differentiates itself with an end-to-end footprint across trusted brands and strong customer support and education, plus direct sales and promotions. Its goal is to help make the world healthier, cleaner, and safer by enabling discovery, diagnostics, and quality manufacturing across research institutions, healthcare providers, and government bodies.

Company Size

10,001+

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

1956

Simplify Jobs

Simplify's Take

What believers are saying

  • Cell therapy developers need automation-ready single-use systems like CTS DynaXS.
  • The Plainville Bioprocess Design Center shortens biologics scale-up before full manufacturing.
  • Ibtrozi manufacturing with Nuvation Bio expands Thermo Fisher into commercial oncology supply.

What critics are saying

  • Sartorius and Danaher pressure pricing with faster, specialized single-use platforms.
  • CDMO competitors Lonza, Catalent, and Samsung Biologics outmuscle Thermo Fisher in commercial manufacturing.
  • Recent layoffs and ongoing restructuring threaten service quality across mission-critical lab operations.

What makes Thermo Fisher Scientific unique

  • Thermo Fisher pairs instruments, reagents, and services across discovery through commercial manufacturing.
  • Its Gothenburg GLP lab supports peptides, antibodies, oligonucleotides, and cell therapies.
  • PPD’s network spans Richmond, Suzhou, and Gothenburg for global bioanalytical coverage.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Thermo Fisher Scientific who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Fertility Treatment Support

Family Planning Benefits

Professional Development Budget

Conference Attendance Budget

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Company News

FinancialContent
May 4th, 2026
Thermo Fisher Scientific unveils an integrated platform to advance scalable Cell Therapy manufacturing.

Thermo Fisher Scientific unveils an integrated platform to advance scalable Cell Therapy manufacturing. Published at May 4th 2026, 8:30 AM EDT via Business Wire i This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. New Gibco(TM) CTS(TM) DynaXS(TM) Single Use Bioreactor supports flexible, cGMP-ready cell expansion from process development to clinical production to support the development of cell therapies for cancer, autoimmune, and other treatments Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Gibco(TM) CTS(TM) DynaXS(TM) Single Use Bioreactor, a purpose-built expansion platform designed to help cell therapy developers scale manufacturing with precise control, flexibility, and regulatory readiness. As cell therapies move from early research into clinical development and commercialization, manufacturers face increasing pressure to transition from static culture systems to scalable, automation-ready platforms that can support consistent quality, cost control, and cGMP compliance. Developers must balance process flexibility with the operational demands of clinical manufacturing, often within limited facility space and tight development timelines. At the same time, the cell therapy landscape continues to evolve beyond oncology into a broader range of indications, including autoimmune and other emerging areas. This shift is driving the development of new cell modalities and diverse manufacturing approaches. These emerging applications often require different process configurations and production scales, adding complexity to manufacturing strategies across all stages of development and commercialization. The CTS DynaXS Single Use Bioreactor was designed specifically to address these evolving needs. The stirred-tank, single-use system supports cell expansion across development and early clinical volumes, offering a scalable platform from small process development batches to larger cGMP manufacturing runs. "Cell therapy manufacturers are navigating a rapidly expanding pipeline and increasing regulatory expectations," said Sara Henneman, vice president and general manager of Thermo Fisher Scientific's cell culture and cell therapy business. "The CTS DynaXS bioreactor reflects our commitment to help deliver end-to-end, integrated solutions that enable customers to simplify scale-up, strengthen process control, and support the development of therapies intended for patient use." Integrated Within the CTS Cell Therapy Ecosystem The CTS DynaXS bioreactor extends Thermo Fisher's Cell Therapy Systems (CTS) portfolio, supporting workflows from cell isolation and activation through expansion and downstream processing. This integration enables customers to build modular, scalable manufacturing strategies with unified technical support and regulatory documentation. "Manufacturers want platforms that grow with them," said Andy Campbell, senior director of research and development at Thermo Fisher Scientific. "With CTS DynaXS, we are providing a solution designed specifically for cell expansion that aligns with the broader cell therapy manufacturing journey. The single-use bioreactor offers a broad operating range and flexible design, enabling customers to efficiently scale from small to large production across a wide variety of volumes, applications, and cell types." Thermo Fisher's Commitment to Cell Therapy Innovation Spans Over 20 Years As demand for scalable, reproducible cell therapy manufacturing solutions accelerates, Thermo Fisher remains committed to supporting customers with technologies designed to reduce complexity, enhance control, and support progress toward clinical development. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of more than $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com. Contacts. Report this content If you believe this article contains misleading, harmful, or spam content, please let us know.

Yahoo Finance
Apr 14th, 2026
Thermo Fisher expands precision health push with HealthVerity data access covering 270M patients

Thermo Fisher Scientific has announced multiple collaborations strengthening its precision health capabilities, including a data partnership with HealthVerity providing access to claims data on over 270 million de-identified US patients across 70 linked sources. The company has also launched proteomics initiatives and new cell therapy tools. The HealthVerity collaboration enhances Thermo Fisher's PPD unit's real-world evidence and trial optimisation services, supporting its ambition to serve as an end-to-end partner in clinical development. The moves deepen the company's integration of large-scale data, high-throughput proteomics and automated manufacturing across the biopharma value chain. The company's narrative projects $50 billion revenue and $9 billion earnings by 2028, requiring 5% annual revenue growth. However, investors face risks from potential margin pressure due to tariffs and policy uncertainty.

The Journal of Healthcare Contracting
Apr 13th, 2026
Thermo Fisher Scientific's PPD clinical research business forms data-focused collaboration.

Thermo Fisher Scientific's PPD clinical research business forms data-focused collaboration. April 13, 2026- Thermo Fisher Scientific announced a strategic data collaboration with HealthVerity, a leading real-world data (RWD) marketplace, to enhance data-driven clinical development and evidence generation for biopharma sponsors. Through the agreement, Thermo Fisher's PPD(TM) clinical research business will gain enterprise-level access to HealthVerity's TaXOnomy(R) claims dataset, representing more than 270 million de-identified patient lives across the U.S. healthcare system. The datasets will provide deep insights into disease prevalence, treatment patterns and provider activity, further strengthening the clinical research business' data and AI driven services across trial feasibility and optimization, recruitment and real-world evidence generation. The agreement also provides access to a marketplace of more than 70 curated data sources, including electronic medical records, laboratory results and other specialty datasets. With streamlined access to longitudinal claims and linked datasets, the business can deliver more precise site selection strategies and improved startup timelines.

Yahoo Finance
Apr 12th, 2026
Thermo Fisher joins Singapore's PRECISE SG100K biobank project for Asia-Pacific precision medicine research

Thermo Fisher Scientific has partnered with Singapore's PRECISE to support the PRECISE SG100K biobank initiative. The company will supply integrated multi-platform proteomics capabilities, including Olink PEA and Orbitrap Astral mass spectrometry, alongside partners Seer and Novogene. The collaboration aims to support population-scale precision medicine research and biomarker discovery across the Asia Pacific region. The stock currently trades at $496.11, approximately 32.7% below the analyst target of $658.40. Thermo Fisher's Life Sciences segment generates $44.6 billion in revenue, with a P/E ratio of 27.5x compared to the industry average of 37.3x. However, analysts note earnings have declined 5% annually over five years, and debt coverage by operating cash flow remains a concern.

PR Newswire Asia
Apr 10th, 2026
NovogeneAIT Genomics appointed as service provider to advance large-scale proteomics for PRECISE-SG100K cohort in Singapore.

NovogeneAIT Genomics appointed as service provider to advance large-scale proteomics for PRECISE-SG100K cohort in Singapore. 2026-04-10 12:44 551 SINGAPORE, April 10, 2026 /PRNewswire/ - NovogeneAIT Genomics announces its appointment as the designated service provider for the PRECISE-SG100K proteomics project. In this role, NovogeneAIT Genomics will process and generate data from 10,000 plasma samples from the PRECISE-SG100K cohort led by Thermo Fisher Scientific in collaboration with PRECISE to support precision medicine research in Singapore. This landmark project will utilize Thermo Fisher Scientific's Orbitrap Astral mass spectrometry platform, coupled with Seer's Proteograph Product Suite and Olink's Reveal Assay. Together, these advanced technologies will enable deep proteomic profiling of 10,000 samples. This study aims to demonstrate the profound value of deep, unbiased plasma proteomics, enabling high-throughput analysis and the discovery of novel biomarkers and biological signatures associated with aging and disease. "Being appointed as the service lab for this landmark study represents a major leap forward in our capability to support large-scale proteomics research in Singapore," said John Zhang, Senior Commercial director of NovogeneAIT. Together, with Thermo Fisher Scientific and Seer, Polkadot PR Pty Ltd is uniquely positioned to deliver deep, actionable insights from this cohort and contribute meaningfully to Singapore's National Precision Medicine Program." Prof. John Chambers, Chief Scientific Officer at PRECISE and lead Principal Investigator of the PRECISE-SG100K cohort, highlighted the importance of this partnership: "This collaboration further strengthens the PRECISE-SG100K dataset, through addition of mass spectroscopy based assessment of proteomic variation. The results will enable our researchers to carry out integrated analyses across different layers of biology. Such efforts are important for improving our understanding of disease mechanisms and supporting future translational research." The successful completion of this 10,000 sample pilot study is expected to serve as a robust proof of concept. It will demonstrate the immense value of complementary proteomics and support the broader expansion of a multi-omics approach for the PRECISE-SG100K cohort. About NovogeneAIT Genomics NovogeneAIT Genomics is a leading multi-omics services and solutions provider headquartered in Singapore. Established as a joint venture between Novogene and AITbiotech, it has grown to become one of the largest multi-omics service providers in Southeast Asia. The company offers a comprehensive suite of services, including genomics, transcriptomics, single cell and spatial transcriptomics, metagenomics and proteomics. NovogeneAIT Genomics delivers high-quality omics solutions to support research across various sectors, including healthcare and agriculture. About PRECISE-SG100K The PRECISE-SG100K study is a landmark long-term research project that has successfully completed its recruitment phase, having engaged over 100,000 participants from Singapore's diverse, multi-ethnic population. This comprehensive study has collected extensive baseline health information and biological specimens from participants across the nation. Moving forward, the study will continue to monitor long-term health outcomes and identify environmental, lifestyle and genetic factors associated with diseases such as diabetes, hypertension, and cancer. As one of the largest population health studies in Southeast Asia, PRECISE-SG100K represents a significant milestone for health research in Singapore and is positioned to yield globally significant results that will advance precision medicine and improve health outcomes for diverse populations worldwide. For more information, please visit Phase II: PRECISE SG100K.

INACTIVE